Abbott/$ABT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abbott
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Ticker
$ABT
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
114,000
ISIN
US0028241000
Website
Abbott Metrics
BasicAdvanced
$233B
17.36
$7.70
0.74
$2.28
1.77%
Price and volume
Market cap
$233B
Beta
0.74
52-week high
$141.23
52-week low
$99.71
Average daily volume
6.2M
Dividend rate
$2.28
Financial strength
Current ratio
1.78
Quick ratio
1.09
Long term debt to equity
26.056
Total debt to equity
31.889
Dividend payout ratio (TTM)
28.92%
Interest coverage (TTM)
14.30%
Profitability
EBITDA (TTM)
11,002.5
Gross margin (TTM)
55.92%
Net profit margin (TTM)
31.89%
Operating margin (TTM)
18.39%
Effective tax rate (TTM)
-83.58%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
6.38%
Return on equity (TTM)
30.65%
Valuation
Price to earnings (TTM)
17.355
Price to revenue (TTM)
5.492
Price to book
4.76
Price to tangible book (TTM)
12.12
Price to free cash flow (TTM)
34.934
Free cash flow yield (TTM)
2.86%
Free cash flow per share (TTM)
382.64%
Dividend yield (TTM)
1.71%
Forward dividend yield
1.77%
Growth
Revenue change (TTM)
5.00%
Earnings per share change (TTM)
139.94%
3-year revenue growth (CAGR)
-1.65%
10-year revenue growth (CAGR)
7.58%
3-year earnings per share growth (CAGR)
21.38%
10-year earnings per share growth (CAGR)
10.77%
3-year dividend per share growth (CAGR)
7.41%
10-year dividend per share growth (CAGR)
9.50%
What the Analysts think about Abbott
Analyst ratings (Buy, Hold, Sell) for Abbott stock.
Bulls say / Bears say
Abbott Laboratories' medical devices unit reported $4.75 billion in Q3 sales, exceeding estimates, driven by a nearly 21% growth in continuous glucose monitors like FreeStyle Libre. (reuters.com)
The company raised its annual profit forecast to $4.64 to $4.70 per share, reflecting confidence in sustained growth. (reuters.com)
Analysts from Wells Fargo and Goldman Sachs have maintained 'Buy' ratings on Abbott Laboratories, citing strong financial performance and growth potential. (markets.businessinsider.com, markets.businessinsider.com)
Abbott faces approximately 1,000 lawsuits alleging its infant formulas caused necrotizing enterocolitis (NEC) in infants, posing significant legal and financial risks. (reuters.com)
The company's nutrition segment underperformed due to an inventory adjustment of pediatric products, indicating potential challenges in this division. (reuters.com)
Abbott's first-quarter profit forecast missed Wall Street expectations, leading to a decline in share value and raising concerns about short-term financial performance. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 23 Jun 2025.
Abbott Financial Performance
Revenues and expenses
Abbott Earnings Performance
Company profitability
Abbott News
AllArticlesVideos
5 Dividend Kings Are Delivering Massive Total Returns of Up to 34% This Year
24/7 Wall Street·2 weeks ago
4 Dividend Aristocrats Are Absolutely Crushing the S&P 500 in 2025
24/7 Wall Street·1 month ago
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
24/7 Wall Street·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abbott stock?
Abbott (ABT) has a market cap of $233B as of June 27, 2025.
What is the P/E ratio for Abbott stock?
The price to earnings (P/E) ratio for Abbott (ABT) stock is 17.36 as of June 27, 2025.
Does Abbott stock pay dividends?
Yes, the Abbott (ABT) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $2.28 and the yield is 1.77%. Abbott has a payout ratio of 28.92% on a trailing twelve-month basis.
When is the next Abbott dividend payment date?
The next Abbott (ABT) dividend payment date is unconfirmed.
What is the beta indicator for Abbott?
Abbott (ABT) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.